In congenital muscular dystrophy, losartan inhibits TGF-β signaling, and downstream phosphorylated Smad2/3 proteins, decreases fibrosis and improves muscle strength. This evidence concerns the gene TGFB1 and congenital muscular dystrophy due to LMNA mutation.